Left atrial appendage closure in patients with atrial fibrillation and acute ischaemic stroke despite anticoagulation.

IF 2.6 1区 医学
Avia Abramovitz Fouks, Shadi Yaghi, Magdy H Selim, Elif Gökçal, Alvin S Das, Ofer Rotschild, Scott B Silverman, Aneesh B Singhal, Sunil Kapur, Steven M Greenberg, Mahmut Edip Gurol
{"title":"Left atrial appendage closure in patients with atrial fibrillation and acute ischaemic stroke despite anticoagulation.","authors":"Avia Abramovitz Fouks, Shadi Yaghi, Magdy H Selim, Elif Gökçal, Alvin S Das, Ofer Rotschild, Scott B Silverman, Aneesh B Singhal, Sunil Kapur, Steven M Greenberg, Mahmut Edip Gurol","doi":"10.1136/svn-2024-003143","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The occurrence of acute ischaemic stroke (AIS) while using oral anticoagulants (OAC) is an increasingly recognised problem among nonvalvular atrial fibrillation (NVAF) patients. We aimed to elucidate the potential role of left atrial appendage closure (LAAC) for stroke prevention in patients with AIS despite OAC use (AIS-despite-OAC).</p><p><strong>Methods: </strong>We retrospectively collected baseline and follow-up data from consecutive NVAF patients who had AIS-despite-OAC and subsequently underwent endovascular LAAC, between January 2015 and October 2021. The primary outcome measure was the occurrence of AIS after LAAC, and the safety outcome was symptomatic intracerebral haemorrhage (ICH).</p><p><strong>Results: </strong>29 patients had LAAC specifically because of AIS-despite-OAC. The mean age at the time of the procedure was 73.4±8.7, 13 were female (44.82%). The mean CHA<sub>2</sub>DS<sub>2</sub>-VASc score was 5.96±1.32, with an expected AIS risk of 8.44 per 100 patient-years. 14 patients (48%) had two or more past AIS-despite-OAC. After LAAC, 27 patients (93.10%) were discharged on OAC which was discontinued in 17 (58.62%) after transoesophageal echocardiogram at 6 weeks. Over a mean of 1.75±1.0 years follow-up after LAAC, one patient had an AIS (incidence rate (IR) 1.97 per 100 patient-years). One patient with severe cerebral microangiopathy had a small ICH while on direct OAC and antiplatelet 647 days after LAAC.</p><p><strong>Conclusions: </strong>LAAC in AIS-despite-OAC patients demonstrated a low annual AIS recurrence rate in our cohort (1.97%) compared with the expected IR based on their CHA<sub>2</sub>DS<sub>2</sub>-VASc scores (8.44%) and to recent large series of AIS-despite-OAC patients treated with OAC/aspirin only (5.3%-8.9%). These hypothesis-generating findings support randomised trials of LAAC in AIS-despite-OAC patients.</p>","PeriodicalId":48733,"journal":{"name":"Journal of Investigative Medicine","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2024-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Investigative Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/svn-2024-003143","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The occurrence of acute ischaemic stroke (AIS) while using oral anticoagulants (OAC) is an increasingly recognised problem among nonvalvular atrial fibrillation (NVAF) patients. We aimed to elucidate the potential role of left atrial appendage closure (LAAC) for stroke prevention in patients with AIS despite OAC use (AIS-despite-OAC).

Methods: We retrospectively collected baseline and follow-up data from consecutive NVAF patients who had AIS-despite-OAC and subsequently underwent endovascular LAAC, between January 2015 and October 2021. The primary outcome measure was the occurrence of AIS after LAAC, and the safety outcome was symptomatic intracerebral haemorrhage (ICH).

Results: 29 patients had LAAC specifically because of AIS-despite-OAC. The mean age at the time of the procedure was 73.4±8.7, 13 were female (44.82%). The mean CHA2DS2-VASc score was 5.96±1.32, with an expected AIS risk of 8.44 per 100 patient-years. 14 patients (48%) had two or more past AIS-despite-OAC. After LAAC, 27 patients (93.10%) were discharged on OAC which was discontinued in 17 (58.62%) after transoesophageal echocardiogram at 6 weeks. Over a mean of 1.75±1.0 years follow-up after LAAC, one patient had an AIS (incidence rate (IR) 1.97 per 100 patient-years). One patient with severe cerebral microangiopathy had a small ICH while on direct OAC and antiplatelet 647 days after LAAC.

Conclusions: LAAC in AIS-despite-OAC patients demonstrated a low annual AIS recurrence rate in our cohort (1.97%) compared with the expected IR based on their CHA2DS2-VASc scores (8.44%) and to recent large series of AIS-despite-OAC patients treated with OAC/aspirin only (5.3%-8.9%). These hypothesis-generating findings support randomised trials of LAAC in AIS-despite-OAC patients.

心房颤动和急性缺血性中风患者在抗凝治疗后仍需关闭左心房阑尾。
背景:非瓣膜性心房颤动(NVAF)患者在使用口服抗凝药(OAC)期间发生急性缺血性卒中(AIS)的问题日益受到重视。我们旨在阐明在使用 OAC 的情况下关闭左心房阑尾(LAAC)对预防 AIS 患者中风(AIS-despite-OAC)的潜在作用:我们回顾性地收集了 2015 年 1 月至 2021 年 10 月间连续接受 AIS-despite-OAC 并随后接受血管内 LAAC 的 NVAF 患者的基线和随访数据。主要结局指标是 LAAC 后 AIS 的发生率,安全结局是无症状性脑内出血(ICH)。手术时的平均年龄为(73.4±8.7)岁,女性 13 例(44.82%)。平均 CHA2DS2-VASc 评分为 5.96±1.32,每 100 患者年的预期 AIS 风险为 8.44。14名患者(48%)既往有两次或两次以上的AIS-despite-OAC。LAAC 后,27 名患者(93.10%)出院时使用 OAC,其中 17 名患者(58.62%)在 6 周后经食道超声心动图检查后停用 OAC。在 LAAC 后平均 1.75±1.0 年的随访期间,一名患者发生了 AIS(发病率(IR)为每 100 患者年 1.97 例)。一名患有严重脑微血管病变的患者在 LAAC 术后 647 天直接服用 OAC 和抗血小板药物期间发生了小量 ICH:在我们的队列中,AIS-despite-OAC 患者的 LAAC 年 AIS 复发率较低(1.97%),而根据患者的 CHA2DS2-VASc 评分,预期的 IR 为 8.44%,近期仅接受 OAC/ 阿司匹林治疗的大型 AIS-despite-OAC 患者的年 AIS 复发率为 5.3%-8.9%。这些假设性研究结果支持对AIS-despite-OAC患者进行LAAC随机试验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Investigative Medicine
Journal of Investigative Medicine MEDICINE, GENERAL & INTERNALMEDICINE, RESE-MEDICINE, RESEARCH & EXPERIMENTAL
自引率
0.00%
发文量
111
期刊介绍: Journal of Investigative Medicine (JIM) is the official publication of the American Federation for Medical Research. The journal is peer-reviewed and publishes high-quality original articles and reviews in the areas of basic, clinical, and translational medical research. JIM publishes on all topics and specialty areas that are critical to the conduct of the entire spectrum of biomedical research: from the translation of clinical observations at the bedside, to basic and animal research to clinical research and the implementation of innovative medical care.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信